Clovis Oncology Inc (CLVS) 2015年年度报告「NASDAQ」.pdf

1、!UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington,D.C.20549 FORM 10-K xANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934.For the fiscal year ended December 31,2015.TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934.For t

2、he transition period from to .Commission file number:001-35347 Clovis Oncology,Inc.(Exact name of Registrant as specified in its charter)Delaware 90-0475355(State or other jurisdiction ofincorporation or organization)(I.R.S.EmployerIdentification No.)5500 Flatiron Parkway,Suite 100Boulder,Colorado 8

3、0301(Address of principal executive offices)(Zip Code)(303)625-5000(Registrants telephone number,including area code)Securities registered pursuant to Section 12(b)of the Act:Title of each class Name of each exchange on which registeredCommon Stock par value$0.001 per share The NASDAQ Global Select

4、MarketSecurities registered pursuant to Section 12(g)of the Act:None Indicate by check mark if the registrant is a well-known seasoned issuer,as defined in Rule 405 of the Securities Act.Yes x No Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Secti

5、on 15(d)of the Act.Yes No xIndicate by check mark whether the registrant(1)has filed all reports required to be filed by Section 13 or 15(d)of the Securities Exchange Act of 1934during the preceding 12 months(or for such shorter period that the registrant was required to file such reports),and(2)has

6、 been subject to such filingrequirements for the past 90 days.Yes x No Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site,if any,every Interactive Data Filerequired to be submitted and posted pursuant to Rule 405 of Regulation S-T(232.405)